Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Conditions
Autoimmune Disease · Crohn Disease · Dermatomyositis · Hematopoietic and Lymphoid Cell Neoplasm · Inflammatory Bowel Disease · Malignant Solid Neoplasm · Multiple Sclerosis · Psoriasis · Psoriatic Arthritis · Rheumatoid Arthritis · Sjogren Syndrome · Systemic Lupus Erythematosus · Systemic Scleroderma · Ulcerative Colitis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Contact: Principal Investigator (Surbhi Singhal)Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
Contact: Principal Investigator (Patricia M. LoRusso)Yale University, New Haven, Connecticut, United States
Contact: Principal Investigator (Patricia M. LoRusso)MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
Contact: Principal Investigator (Geoffrey T. Gibney)Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
University of Kansas Clinical Research Center, Fairway, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)HaysMed, Hays, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Cancer Center, Kansas City, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)Lawrence Memorial Hospital, Lawrence, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)Mercy Hospital Pittsburg, Pittsburg, Kansas, United States
Salina Regional Health Center, Salina, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Contact: Principal Investigator (Susanne M. Arnold)Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Contact: Principal Investigator (Julie R. Brahmer)National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
Contact: Principal Investigator (A P. Chen)National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Patrick A. Ott)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Patrick A. Ott)Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Contact: Principal Investigator (Tanner M. Johanns)Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Contact: Principal Investigator (Tanner M. Johanns)University Health Truman Medical Center, Kansas City, Missouri, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Cancer Center - North, Kansas City, Missouri, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
Contact: Principal Investigator (Joaquina C. Baranda)University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States
Contact: Principal Investigator (Joaquina C. Baranda)Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Tanner M. Johanns)Siteman Cancer Center-South County, St Louis, Missouri, United States
Contact: Principal Investigator (Tanner M. Johanns)Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
Contact: Principal Investigator (Tanner M. Johanns)Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Contact: Principal Investigator (Sarah A. Weiss)NYU Langone Hospital - Long Island, Mineola, New York, United States
Contact: Principal Investigator (Janice M. Mehnert)Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Contact: Principal Investigator (Janice M. Mehnert)NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@cumc.columbia.edu · 212-342-5162Contact: Principal Investigator (Brian S. Henick)NYP/Weill Cornell Medical Center, New York, New York, United States
Contact: Principal Investigator (Ashish Saxena)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Yuanquan Yang)Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Yana Najjar)UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas, United States
Contact: Study coordinator (Site Public Contact) · canceranswerline@utsouthwestern.edu · 214-648-7097Contact: Principal Investigator (Hans Hammers)UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Contact: Study coordinator (Site Public Contact) · canceranswerline@UTSouthwestern.edu · 214-648-7097Contact: Principal Investigator (Hans Hammers)UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas, United States
Contact: Study coordinator (Site Public Contact) · canceranswerline@UTSouthwestern.edu · 214-648-7097Contact: Principal Investigator (Hans Hammers)M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Ecaterina E. Ileana Dumbrava)UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas, United States
Contact: Principal Investigator (Hans Hammers)Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States
Contact: Principal Investigator (Andrew Poklepovic)University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Study leads
Hussein A Tawbi
Principal Investigator
University of Texas MD Anderson Cancer Center LAO